Skye Bioscience Inc. has released a corporate presentation detailing its developments in the field of obesity treatment. The company is working on pioneering the first CB1 antibody, nimacimab, which aims to address the needs of patients who do not respond to or cannot tolerate existing GLP-1 drugs. The presentation highlights the crowded nature of the GLP-1 space, noting issues with safety and adherence. It also discusses the opportunity for nimacimab to offer a combination option for additional weight loss. Skye Bioscience is focused on addressing fundamental drivers of metabolic diseases, such as increasing energy expenditure and targeting adipose tissue to reduce fat mass. You can access the full presentation through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。